The latest national report from the UK shows that 2019 marks an important milestone. The rate of new HIV diagnoses has gone down significantly among all groups. The reduction is particularly notable among one high risk segment – gay and bisexual men.

A new study suggests new opportunities for the prevention of HIV through the use of injectable PrEP. The study focuses exclusively on women living in Sub-Saharan Africa and it suggests that cabotegravir could deliver much better results as a form of HIV prevention than Truvada.

The human immunodeficiency virus (HIV) compromises the functioning of the immune system. This is the main reason why healthcare professionals have expressed a lot of concern about the way HIV-positive people could be affected by Covid-19. Have their fears of negative outcomes come true? Here’s what data shows so far.

The World Health Organization (WHO) is constantly upgrading its recommendations for the treatment of HIV and AIDS. A new meta-analysis has now shown that dolutegravir, a type of antiretroviral medication, can be recommended as a first-line treatment option for people who are newly diagnosed as HIV positive.

UNAIDS released its latest report on HIV infection rates since 2010 to 2019. While the rate of new infections has slowed down significantly, the world is still far away from the goal set for 2020 and the projected elimination of the HIV virus by 2030.

Elite controllers are a very small group of people whose immune system can suppress the HIV virus without the need for additional medications. A recent study carried out among a group of elite controllers has discovered exactly how their immunity works.

The early stage of HIV can be difficult to recognise due to the fact that the infection causes non-specific symptoms. Many people will have no signs of infection whatsoever. As a result, the best way to determine whether someone is HIV-positive is to get tested in an accredited medical facility.

Three quarters of the women who are HIV-positive live in Sub-Saharan Africa. This is why UNAIDS is putting a lot of work and effort into the research and development of a preventative option for these women. New announcements suggest that the efforts are likely to pay off in the near future.